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ANALYSIS
Guideline groups in the United Kingdom and the 
United States are reviewing recommendations for 
the primary prevention of cardiovascular disease. 
At their disposal will be good quality evidence on 
the quantitative relation between the major risk 
factors and the probability of a first cardiovascular 
event1; the extent of the current population expo-
sure to risk factors2  3; and the safety and efficacy 
of drugs to lower blood pressure and cholesterol 
concentrations.4  5 The decisions of these expert 
groups will have far reaching consequences for the 
millions of adults in both countries, where cardio-
vascular disease is the biggest cause of mortality 
and morbidity; around half of men and a third of 
women have a cardiovascular event during their 
life.6
There are new drivers to modify the existing 
guidance (see table 1 online at bmj.com; box), 
and two extreme positions could be envisaged 
(table 2). The first is to redouble efforts to iden-
tify high risk individuals by enhancing currently 
used risk prediction tools with new information 
from blood biomarkers or non-invasive vascular 
imaging; to treat those at high risk with newer 
more expensive statins that achieve the greatest 
cholesterol reduction; and to tailor treatment for 
each individual to achieve target cholesterol levels. 
The interest in C reactive protein as a new biomar-
ker of cardiovascular risk7 and the recent US Food 
and Drug Administration licence extension of the 
patent for rosuvastatin, with C reactive protein 
as a companion test, suggests that the US could 
follow this course. The diametric alternative is to 
use generic versions of the older statins in a wider 
population by including people whose risks fall 
below the current absolute risk thresholds for drug 
intervention and to dispense with a target choles-
terol level. In the UK, eligibility criteria for statins 
in primary prevention have been relaxed over the 
years and a switch to generic statins, where pos-
sible, is already saving substantial sums.8
But is the first approach an unacceptably expen-
sive strategy that fails to exploit increased oppor-
tunity for disease prevention from wider access to 
effective, safe, inexpensive generic statins? Is the 
second insufficiently refined for an era of person-
alised or stratified medicines where the aim is to 
maximise individual benefit and minimise harm?
High risk individual v population based 
approaches
Geoffrey Rose developed the important concept 
of the “prevention paradox”: that more cases of 
cardiovascular disease occur among the majority 
at average risk than among the minority at high 
risk.9 The paradox arises because risk factors such 
as cholesterol and blood pressure are a contin-
uum. Each exhibits a log-linear association with 
risk of coronary heart disease with no safe thresh-
old, while the population risk factor exposure 
follows a normal distribution.10 A consequence 
is that the distribution of blood pressure and 
cholesterol values overlaps substantially among 
those who do and do not develop coronary 
events later in life, leading to a seemingly 
counterintuitive observation that risk fac-
tors such as low density lipoprotein (LDL) 
cholesterol are poor predictors of clinical 
events despite being causally related to coro-
nary heart disease.
The prevention paradox leads to a tension. 
Focusing exclusively on people with high lev-
els of one risk factor, or at high absolute risk of 
a clinical event calculated from multiple risk 
factors, overlooks the burden of events that will 
occur among the average majority. Conversely, a 
population based strategy, which seeks to address 
How should we balance individual 
and population benefits of statins for 
preventing cardiovascular disease?
US and UK groups revising recommendations on primary prevention of cardiovascular disease  
will have to decide whether to concentrate on high risk individuals or the whole population.  
Aroon Hingorani and Harry Hemingway argue that the evidence favours a population approach
Table 2 | Population versus high risk strategies for primary prevention of cardiovascular disease
Population based High risk individuals
Who to treat? People at lower absolute risk of 
cardiovascular disease using established risk 
equations with lower treatment thresholds or 
people above an age threshold
People whose absolute risk of cardiovascular disease 
exceeds thresholds based on established risk equations 
with addition of new markers (eg, C reactive protein, carotid 
intima-media thickness, genotype)
What to treat with? Inexpensive generic statins, perhaps in 
combination with generic blood pressure 
lowering drugs
Generic statins for those at moderate risk; newer, more 
potent statins for those at highest risk
What target? None Targets based on LDL cholesterol, blood pressure, or 
absolute risk, with regular monitoring and titration of drugs
this, leads to people at low individual risk being 
exposed to an intervention with less personal 
gain. The merits of each approach are intimately 
linked to the efficacy, safety, cost, and conven-
ience of the available interventions. In Rose’s era, 
the lipid lowering drugs were poorly tolerated and 
only modestly effective. For this reason, dietary 
and lifestyle interventions became aligned with 
the population approach, the aim being to achieve 
a large overall benefit by even modest shifts in the 
risk factor distribution in the whole population.
Primary prevention in the early statin era
The first statins to market were better tolerated and 
lowered cholesterol more effectively than the pre-
ceding drugs.11 
However, their 
broader use in 
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primary prevention was constrained initially by the 
high costs and uncertainty about long term safety. 
An individualised approach to primary prevention 
therefore persisted in the UK based on absolute 
risk. Absolute risk was chosen rather than LDL cho-
lesterol because LDL cholesterol on its own poorly 
differentiates those who will have events and two 
people with the same LDL cholesterol concentra-
tion can have widely differing risks of coronary 
heart disease depending on 
other risk factors such as age, 
sex, smoking habits, and 
blood pressure.12 Targeting 
statins on the basis of abso-
lute risk makes the justifiable 
assumption that the relative 
risk reduction from statin 
treatment is constant (such 
that the absolute benefit and 
number needed to treat are 
proportional to absolute risk) 
and that the particular con-
stellation of risk factors in an 
individual does not modify 
the treatment effect.13 Stat-
ins are as effective in people 
whose cardiovascular risk is 
mainly influenced by high 
blood pressure or diabetes as 
among people whose cholesterol concentration is 
the main determinant of risk.
Europe and Australasia have broadly adopted a 
similar absolute risk based approach to interven-
tion, which has encouraged use of computerised, 
point of care risk assessment tools based on results 
from observational studies like the US Framing-
ham Heart Study or routinely collected clinical 
data such as QRISK in the UK.14 However, in the US, 
where risk assessment was initially based on LDL 
cholesterol alone, guidelines continue to recom-
mend consideration of both LDL cholesterol and 
absolute risk when prescribing statins for primary 
prevention.
Why change guidance?
The absolute risk based approach has limitations. 
Risk assessment models assign individuals to 
groups with observed event rates close to those 
predicted. But they perform little better than their 
constituent variables (for example, age, blood pres-
sure, and cholesterol) in differentiating individuals 
who eventually have events.15 Just as with choles-
terol, many cardiovascular events occur in people 
at intermediate risk, below current thresholds for 
statin eligibility.
Raised concentrations of blood biomarkers such 
as C reactive protein and subclinical atherosclero-
sis in the carotid or coronary artery, detected by 
ultrasonography or computed tomography, have 
been associated with a higher risk of cardiovascu-
lar events. And at the same time, the cost of the 
first statins to market (simvastatin, pravastatin, 
etc) is dropping abruptly because their patents 
have expired. For example, generic simvastatin 
40 mg daily now costs less 
than £1.40 (€1.60; $2.30) 
a month compared with 
£24.64 a month for 20 mg 
atorvastatin, the patent on 
which expires next year. 
Evidence of long term safety 
is available for established 
statins but not yet for the 
newer drugs. These devel-
opments are opening up two 
approaches to deal with the 
current limitations of  abso-
lute risk assessment based 
on established risk factors.
The first seeks to apply 
new technology, whether 
biomarkers or imaging 
tools, to identify more accu-
rately people at intermedi-
ate risk who will have events. The second seeks to 
circumvent the inherent difficulties in prediction 
altogether by simply offering statins to a wider 
range of adults than would currently be treated. In 
effect, this represents a shift towards a population 
based approach to prevention that includes use of 
cholesterol lowering drugs as well as dietary and 
lifestyle measures. How do the options compare?
New tools for risk assessment
The European view is that C reactive protein is little 
better than cholesterol at predicting risk (for similar 
reasons) and adds little to existing risk models.16 
However, C reactive protein is already considered 
an option for risk assessment in the US, based in 
part on a recommendation from the American 
Heart Association and Centers for Disease Control 
and Prevention17 and is now established in Cana-
dian guidelines.18
A recent meta-analysis found that thickness 
of the carotid intima-media and identification of 
plaque were insufficiently useful for screening peo-
ple at intermediate risk,19 and comparison trials 
have not been conducted for primary p revention. 
It is therefore unsurprising that n either carotid nor 
coronary imaging has yet been adopted by the NHS 
Pressures for changing primary 
prevention strategy
Drivers for widening statin eligibility
Reduced cost through patent expiry 
and availability of inexpensive generic 
formulations with excellent long term 
safety profile
• Policy emphasis on disease 
prevention
• Development of polypill concept
Drivers for more individualised 
primary prevention
• Emphasis on personalised medicine
• Claimed predictive value of new 
biomarkers and imaging tools such 
as C reactive protein, carotid intima-
media thickness, and coronary 
artery calcification
for primary prevention and that the American Heart 
Association, the American College of Cardiology, 
and the US Preventative Services Task force have 
been cautious about their role in predicting risk.20  21 
Despite this, the newly enacted Texas Heart Attack 
Prevention Bill requires health insurers to cover up 
to $200 towards the cost of measuring coronary 
calcium or carotid intima-media thickness every 
five years. The bill followed publication of guide-
lines from the Society for Heart Attack Prevention 
and Eradication (SHAPE) task force,22 which were 
not part of the established guideline development 
framework of the American College of Cardiology 
or American Heart Association.23
Wider use of generic statins
The most recent guidelines from the Scottish 
Intercollegiate Guidelines Network (SIGN) and the 
National Institute for Health and Clinical Excellence 
(NICE) lowered the risk threshold for prescribing 
statins from a 10 year coronary heart disease risk 
of 30% (roughly equivalent to a 10 year cardiovas-
cular disease risk of 45%) adopted in the UK soon 
after the introduction of statins, to a 10 year cardio-
vascular disease risk of 20% (roughly equivalent to 
a 10 year coronary heart disease risk of 15%). The 
proposed Department of Health vascular health 
checks for all 40-74 year olds would also move from 
opportunistic testing of cardiovascular risk factors 
in primary care to systematic identification of all 
eligible adults.24
But are the new risk thresholds and vascular 
health checks an equitable means of expanding 
the use of statins? Around half of men aged over 
50 years in England and Wales will now be eligible 
for statins, but a substantial proportion of all events 
would be expected in men of this age group whose 
risk falls below the threshold of 20%, arguably 
leading to inequity of access to statins. Furthermore 
there are unresolved concerns about the extent to 
which risk thresholds may address, or exacerbate, 
social inequalities in vascular risk.25 The number 
needed to screen in the vascular checks to prevent 
one event is also estimated to be high: 449 for men 
and 1638 for women.26 
An alternative is to offer statins on the basis of 
age with no risk factor screening. Over 95% of car-
diovascular events occur after the age of 50, and 
age is the overarching determinant of absolute 
risk.27 Age on its own may be nearly as effective 
in discriminating cardiovascular events as risk 
equations that incorporate additional variables. 
Age based eligibility for statins would obviate the 
need for risk factor screening and reduce potential 
inequity of access to statins. However, it would 
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result in large numbers of adults at low risk taking 
drugs for many years, which may make it difficult 
to implement. 
 Is there any role for newer more expensive 
statins? 
 A lower “on-treatment” LDL cholesterol level within 
trials and a larger average LDL cholesterol reduc-
tion across trials have been associated with greater 
reductions in cardiovascular risk. As a result, some 
guidelines on primary prevention have proposed 
treatment to target cholesterol concentrations. 28 
However, the cost effectiveness of more intensive 
lowering of cholesterol with expensive patented 
statins (such as rosuvastatin) versus less intensive 
lowering with cheaper generic drugs has not been 
evaluated in primary prevention. Moreover, some-
one taking simvastatin but failing to reach an arbi-
trary cholesterol target may stand to gain a similar 
or greater reduction in cardiovascular risk from 
the addition of an inexpensive generic blood pres-
sure lowering drug as from a switch to a different 
statin. The principle of targeting multiple risk fac-
tors simultaneously to maximise risk reduction at 
low cost is being evaluated in trials of combination 
tablets containing generic blood pressure lowering 
drugs and statins (polypills). 29 
 From guidelines to health policy 
 Rose recognised that strategies for preventing 
cardiovascular disease have sociopolitical reper-
cussions and their development could benefit 
from involvement not only of medical experts but 
also policy makers and patients. Studies are now 
required to evaluate the preferences of people 
being targeted for primary prevention, who have 
yet to be properly invited to the debate and to 
formally model the cost effectiveness of the dif-
ferent screening options. Prevention is now high 
on the health agenda. Recent guidance from NICE 
on prevention of cardiovascular disease at popu-
lation level 30 is aimed at “government, the NHS, 
local authorities, industry and all those whose 
actions influence the population’s cardiovascular 
health” and focuses on “legislative, regulatory, and 
voluntary changes” relating to salt, saturated fat 
and trans fat consumption, food marketing and 
labelling, public sector catering, and increasing 
physical activity. 
 Conclusion 
 In an era of safe, inexpensive generic statins 
where new methods for risk assessment poorly 
discriminate cases of cardiovascular disease, the 
balance of evidence appears currently to favour 
wider eligibility for statins, as part of a broader 
population based effort to reduce cardio vascular 
risk. However, should new preventive treatments 
of uncertain long term safety emerge from ongoing 
clinical trials, these would again need to be tar-
geted at people at highest risk, applying the most 
cost effective screening tools available. 
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Vascular disease affects more than four million 
people in England.1 It is responsible for 170 000 
deaths a year in England (36% of all deaths) and 
one fifth of hospital admissions, and it is the larg-
est single cause of long term ill health and dis-
ability. To try to reduce the high prevalence and 
costs, the National Health Service health checks 
programme for adults aged 40 to 74 years was 
introduced in England in April 2009, with full 
implementation planned for 2012-13. 
The objective of the programme is to assess 
risk of developing vascular or metabolic disease 
(heart attack, angina, stroke, diabetes, and kid-
ney disease) and manage the risk factors to pre-
vent progression and improve outcomes (box 1). 
These diseases have shared risk factors including 
smoking, high blood pressure, obesity, physical 
inactivity, and impaired glucose regulation. An 
integrated approach to their identification and 
management is therefore likely to be more cost 
effective. The Department of Health estimates 
that if there is universal uptake across the 
country, the programme could prevent 
9500 myocardial infarctions and 
strokes each year.1 
Advoca te s 
of these 
 proposals hope that successful implementation 
may reduce health inequalities in the population 
by identifying people at risk of disease or with 
undiagnosed disease earlier. However, many 
unanswered questions remain.
Is there evidence of benefit?
Programmes to identify and manage vascular risk 
have never been implemented on this scale, and 
estimates of the effectiveness and cost effective-
ness rely on modelling studies.3 Economic model-
ling by the Department of Health suggests that the 
programme will cost £332m (€380m; $540m) a 
year when fully implemented and that the average 
annual benefit will be £3.8bn.3 It also reported 
that the programme would cost around £3500 per 
quality adjusted life year (QALY) gained.
The current guidance for primary prevention 
of cardiovascular disease recommends multifac-
torial risk factor management with both drugs 
and lifestyle interventions. Although there is no 
evidence of harm from health checks,4 trials, 
including the multiple risk factor intervention 
study (MRFIT)5 and the UK nurse intervention 
OXCHECK study,6 have not shown any benefit on 
hard outcomes. The National Institute for Health 
and Clinical Excellence (NICE) guidelines for use 
of statins recommend targeted case finding rather 
than a population approach.7 In addition, a recent 
modelling study has suggested risk stratification 
using routinely available computer data and 
inviting only those at high risk is more 
likely to be effective for primary 
prevention.8 However, the 
Department of Health 
economic modelling 
primarily considered 
universal screen-
ing.3
Everybody 
identi f ied 
as being 
at high 
r i s k 
Unanswered questions 
over NHS health checks
England plans to target vascular disease by offering  all adults 
aged 40-74 a regular health check, but Kamlesh Khunti and 
colleagues point out that success is far from guaranteed
by screening will be offered lifestyle interven-
tion programmes, including advice on physical 
activity. Currently only 20-25% of the UK adult 
population adhere to the recommended guide-
lines. Although the evidence from epidemiolog-
ical studies of the effect of physical activity on 
cardiovascular outcomes is compelling, interven-
tion studies to encourage physical activity have 
not realised the potential benefits. Furthermore, 
one recent study found that people taking drugs 
to manage risk factors are less likely to be physi-
cally active,9 which may imply that the drugs give 
false reassurance. 
Intensive lifestyle interventions have been 
shown to prevent type 2 diabetes in those at 
high risk,10 and the Department of Health’s 
economic modelling calculated lifestyle inter-
vention costs for people with impaired glucose 
regulation as the largest single cost: 42% com-
pared with 21% for antihypertensive drugs 
and statins.3 However, programmes of inten-
sive intervention are not currently available in 
primary care and have not been tested in prag-
matic trials. In view of these uncertainties on 
effectiveness, full implementation of the health 
checks programme should await further data 
from the health checks pilots.2
When to screen
The health checks programme recommends 
rescreening every five years for those found to 
be at low risk and does not recommend starting 
screening at an earlier age for people in high 
risk groups.1 However, a recent modelling study 
has suggested that screening for type 2 diabetes 
is cost effective when started at age 30-45 years 
with rescreening every three to five years.11 
Risk assessment
Weight, height, blood pressure, and lipid meas-
urements are interpreted in combination with 
information obtained from the history and exam-
ination using risk assessment tools (figure). If 
the cardiovascular risk is greater than 20% over 
10 years then a statin is recommended to lower 
cholesterol levels. The Department of Health 
includes both Framingham and QRISK2 in the 
bmj.com/archive
 ЖCochrane review questions evidence for 
statins for primary prevention in low risk groups 
(BMJ 2011;342:d480) 
 ЖUnintended effects of statins in men and 
women in England and Wales  
(BMJ 2010;340:c2197)
 ЖShould statins be prescribed for primary 
prevention of cardiovascular disease in  
patients with chronic kidney disease?  
(BMJ 2009;339:b294)
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health checks guidelines, and primary care trusts 
have been left to decide which tool to use.
For chronic kidney disease, the programme 
recommends that people with a blood pressure 
≥140/90 mm Hg have their  serum creatinine 
measured to calculate the estimated glomerular 
filtration rate.1 Evidence for this is controver-
sial, and studies have suggested that estimated 
glomerular filtration rate and proteinuria are both 
independent predictors of future cardiovascular 
risk.12 Although assessment for proteinuria is not 
currently recommended as an initial assessment 
tool, there is potential to incorporate and evaluate 
this in current pilots.
A key element of the programme is identifying 
people with type 2 diabetes and those at risk of dia-
betes. There is national and international debate 
about how best to screen and diagnose diabetes. 
NHS health checks guidance recommends using 
presence of obesity and hypertension as a prag-
matic way to identify those at risk and to measure 
fasting serum glucose or haemoglobin A1c concen-
tration.1 An international expert committee has 
called for the use of haemoglobin A1c instead of 
an oral glucose tolerance test to diagnose diabe-
tes,13 and it would therefore be sensible to include 
haemoglobin A1c as part of the health check.14
Challenges to implementation 
Location
Key elements of the programme include risk 
assessment, risk communication, management, 
and appropriate recall. The Department of Health 
has not said how to implement the programme, 
and primary care trusts are taking different 
approaches. Screening can be offered in vari-
ous community settings such as pharmacies and 
places of worship to enhance uptake and acces-
sibility to local populations. 
The Department of Health has suggested that 
Box 1 | NHS health checks programme
•	Adults	aged	40	to	74	years	without	a	diagnosis	
of	vascular	disease	will	be	contacted	by	their	
primary	care	trust	and	offered	a	health	check
•	Risk	assessment	includes	collection	of	
demographic	data,	family	history,	smoking	
status,	cholesterol	and	blood	pressure	
measurement,	and	a	diabetes	filter	(figure)
•	An	individualised	management	plan	is	then	
developed	according	to	the	risk	assessment
•	Currently	19	“test	bed	sites”	are	piloting	the	
health	checks
•	In	most	pilots	the	checks	are	being	done	by	
nurses	or	pharmacists	in	various	community	
locations
•	Piloted	programmes	are	being	evaluated,	with	
data	available	on	the	learning	network	website2
•	Phased	roll-out	of	the	programme	will	
follow	evaluation	of	these	pilots	with	full	
implementation	by	2012-13
Age
Disease
or
high
risk
register
Recall
Risk assessment
Blood sugar test
If at risk
Sex
Smoking status
Physical activity
Family history
Ethnicity
Body mass index
Behaviour change
tool – eg, Mid-life
life check
Oral glucose
tolerance test
Assessment for
hypertension
Risk managementCommunication of risk
Risk
assessment
NHS stop smoking
services referral
Exercise on
prescription or
other physical
activity
intervention
Weight
management
on referral
Chronic kidney
disease
assessment
Lifestyle
management
advice
Statins offered
Antihypertensives
Cholesterol test
Blood pressure
Diabetes filter
Serum
creatinine
If risk >20%
eGFR low
High
If
high
Raised
If impaired
fasting
glucose
or glucose
tolerance
NHS programme for assessing and managing risk of vascular disease1
services could also be commissioned from the 
private sector.1 However, this has potential risks, 
such as duplication of screening, occasional 
discrepancies in results, increasing inequalities 
by not engaging appropriate target groups, and 
inappropriate use of scarce healthcare resources. 
If these problems can be overcome, delivery by 
different organisations is to be welcomed because 
it is more likely to be appropriate for the needs of 
the local population. However, a key challenge 
will be quality assurance, details of which are 
currently lacking. Additionally, the challenges 
of data communication between providers and 
primary care need to be overcome.
Uptake
The Department of Health cost effectiveness mod-
elling assumes a 75% uptake.3 A recent pilot in 
one region reported response rates of 29%, with 
even fewer attending for follow-up.15 Furthermore, 
response rates for screening programmes are low 
in areas of socioeconomic deprivation and multi-
ethnic communities,16 which could widen dispari-
ties in these groups. Reasons for low response in 
these groups are complex and include variations in 
health beliefs and help seeking behaviour.
Population diversity 
Decisions about when and who to screen are par-
ticularly important because the UK population is 
so diverse and the incidence of vascular disease 
variable. South Asians, for example, have a 50% 
higher mortality from coronary heart disease than 
white Europeans.17 The health check is being 
offered to people over 40 years of age, but the age 
of onset of di abetes or cardiovascular disease in 
South Asians is around a decade earlier,18 partly 
because a higher proportion have risk factors at a 
younger age.18 Furthermore, a body mass index of 
27.5 has been suggested as a threshold for inter-
vention for people of South Asian and Chinese 
ethnicity, with recent data suggesting even lower 
thresholds.19 However, at the moment there is no 
plan to adjust the programme’s criteria according 
to ethnicity.
Workload
Implementation will be challenging in an already 
overstretched primary care. Around 20% of peo-
ple screened are expected to be at high risk,1 and 
this figure is likely to be higher in some areas. 
NHS Nottingham found 66% of patients recruited 
in their pilot NHS health check, who were mainly 
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from areas of high deprivation, had a cardiovascu-
lar risk of greater than 20% over 10 years. 20 
 General practices will need to provide a substan-
tial number of additional 
appointments for risk 
assessments and follow-
up. A typical surgery 
list size of 5600 people 
would have to provide 
330 vascular checks 
a year, or five to six a 
week. 1 However, most 
of the check, including 
support to help people 
manage their risk, does 
not need to be carried 
out by general practi-
tioners. Existing serv-
ices such as community 
dietitians, smoking reso-
lution clinics, and active 
lifestyle schemes are 
also likely to experience 
an increased wo rkload.  
 NHS health checks are 
expected to be done in primary care, and primary 
care trusts are negotiating with general practi-
tioners to provide this programme as a locally 
enhanced service with remuneration provided for 
each patient assessed. Some primary care trusts 
have also developed a new structured initiative 
scheme that includes financial rewards for general 
practitioners reaching locally agreed targets for the 
NHS health checks programme. 21 
 Information technology 
 Although primary care computer systems capture 
data on risk factors and prescriptions, they contain 
little information on lifestyle factors such as physi-
cal activity and diet. Computer templates to allow 
this information to be captured will be essential to 
evaluate improvements in lifestyle factors. Further-
more, the Department of Health funded diabetes 
screening pilot identified several practical obsta-
cles including screening occurring ad hoc outside 
the eligibility criteria, poor follow-up of individuals 
who were found to be at risk, and poor data cap-
ture in general practice computer systems. 16 These 
deficiencies must not be repeated in the current 
programme. 
 Conclusions 
 The NHS Health checks programme is one of the 
most ambitious attempts to universally detect and 
reduce vascular and metabolic risk and should be 
 Box 2 | Key challenges and uncertainties of the 
NHS health check programme 
•		Evidence	of	effectiveness	and	cost	
effectiveness	is	lacking	except	from	modelling	
studies	
•		Recent	modelling	studies	suggest	the	
programme	is	likely	to	be	cost	effective	if	
targeted	at	high	risk	groups	
•		Uptake	of	screening	programmes	is	low	in	
areas	of	socioeconomic	and	multiethnic	
communities		
•		Recommended	intensive	lifestyle	
interventions	for	prevention	are	not	currently	
available	in	primary	care	
•		Interventions	to	increase	physical	activity	have	
had	limited	success	
•		Implementation	is	likely	to	be	challenging	in	
an	already	overstretched	primary	care	
•		Information	technology	to	capture	and	transfer	
data	between	organisations	providing	health	
checks	is	not	yet	available	
welcomed. By focusing on prevention rather than 
cure, the programme is an important attempt 
to allow people who may otherwise not access 
healthcare services, an 
opportunity to do so. 
 In order for the pro-
gramme to succeed, 
primary care trusts 
(and, in future, com-
missioners) and prac-
tices will need to work 
in close partnership 
and negotiate how 
the programme can 
be feasibly provided. 
Several challenges will 
need to be overcome 
(box 2), and learning 
from the pilots before 
fu l l  implementa -
tion will be essential. 
Finally, robust evalu-
ation of cardiovascu-
lar outcomes and cost 
effectiveness will be 
required to determine the benefits of the pro-
gramme and to ensure inequalities are not being 
widened. 
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not access healthcare services, an opportunity to do so
